Literature DB >> 30097413

First results from the Swedish National Pancreatic and Periampullary Cancer Registry.

Bobby Tingstedt1, Bodil Andersson2, Claes Jönsson3, Victoria Formichov4, Svein-Olav Bratlie3, Mikael Öhman5, Britt-Marie Karlsson6, Christophe Ansorge7, Ralf Segersvärd7, Thomas Gasslander8.   

Abstract

BACKGROUND: Despite improvements in therapy regimens over the past decades, overall survival rates for pancreatic and periampullary cancer are poor. Specific cancer registries are set up in various nations to regional differences and to enable larger prospective trials. The aim of this study was to describe the Swedish register, including possibilities to improve diagnostic work-ups, treatment, and follow-up by means of the register.
METHODS: Since 2010, all patients with pancreatic and periampullary cancer (including also patients who have undergone pancreatic surgery due to premalignant or benign lesions) have been registered in the Swedish National Periampullary and Pancreatic Cancer registry.
RESULTS: In total 9887 patients are listed in the registry; 8207 of those have malignant periampullary cancer. Approximately one-third (3282 patients) have had resections performed, including benign/premalignant resections. 30-day and 90-day mortality after pancreatoduodenectomy is 1.5% and 3.5%, respectively. The overall 3-year survival for resected pancreatic ductal adenocarcinoma is 35%. Regional variations decreased over the studied period, but still exist.
CONCLUSION: Results from the Swedish National Registry are satisfactory and comparable to international standards. Trends over time show increasing resection rates and some improved results. Better collaboration and openness within pancreatic surgeons is an important side effect.
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30097413     DOI: 10.1016/j.hpb.2018.06.1811

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  8 in total

1.  Centralization of Pancreatic Surgery in Europe: an Update.

Authors:  Kjetil Søreide; Linn S Nymo; Kristoffer Lassen
Journal:  J Gastrointest Surg       Date:  2019-09-04       Impact factor: 3.452

2.  Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort.

Authors:  Linn Såve Nymo; Tor Åge Myklebust; Hanne Hamre; Bjørn Møller; Kristoffer Lassen
Journal:  BJS Open       Date:  2022-03-08

3.  Preoperative Risk Score for Early Mortality After Up-Front Pancreatic Cancer Surgery: A Nationwide Cohort Study.

Authors:  Paulina Bereza-Carlson; Johan Nilsson; Bodil Andersson
Journal:  World J Surg       Date:  2022-08-08       Impact factor: 3.282

4.  Factors associated with healthcare utilisation during first year after cancer diagnose-a population-based study.

Authors:  Helena Ullgren; Lena Sharp; Anna Olofsson; Per Fransson
Journal:  Eur J Cancer Care (Engl)       Date:  2020-11-20       Impact factor: 2.520

5.  Predictive Factors for Postoperative Pancreatic Fistula-A Swedish Nationwide Register-Based Study.

Authors:  C Williamsson; K Stenvall; J Wennerblom; R Andersson; B Andersson; B Tingstedt
Journal:  World J Surg       Date:  2020-08-20       Impact factor: 3.352

6.  Centralizing a national pancreatoduodenectomy service: striking the right balance.

Authors:  L S Nymo; D Kleive; K Waardal; E A Bringeland; J A Søreide; K J Labori; K E Mortensen; K Søreide; K Lassen
Journal:  BJS Open       Date:  2020-09-07

7.  Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma.

Authors:  Mikael Öman; Yvonne Wettergren; Elisabeth Odin; Sofia Westermark; Peter Naredi; Oskar Hemmingsson; Helena Taflin
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-16       Impact factor: 3.333

8.  Surgical exploration without resection in pancreatic and periampullary tumors: Report from a national database.

Authors:  Emil Sahlström; Johan Nilsson; Bobby Tingstedt; Magnus Bergenfeldt; Roland Andersson; Bodil Andersson
Journal:  Scand J Surg       Date:  2020-04-17       Impact factor: 2.360

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.